MD IMPORT TEST
MD HEADING
Body Example
Body Example
{content}
If you've spent any time looking at NAD+ supplements, you've run into the NMN versus NR debate. Both molecules are NAD+ precursors. Both have human trial data. Both have advocates and critics. The honest answer is that they're more similar than the marketing wars suggest, with a few real differences that matter for specific situations. This piece compares them on mechanism, evidence, regulatory status, and practical use, and gives you a defensible answer to which one you should consider.
Both molecules are forms of vitamin B3 metabolites that feed the salvage pathway your cells use to rebuild NAD+.
So the relationship is simple. NR is one biochemical step further from NAD+ than NMN. NR has to be phosphorylated first (by NRK) before it can be used. NMN skips that phosphorylation step.
The argument NMN advocates make: NMN is one step closer to NAD+, so it's more efficient. The argument NR advocates make: NR is more easily transported into cells, so it's more bioavailable. Who's right?
Both, partly. The phosphate group on NMN does block direct entry into most cells through the nucleoside transporters that NR uses. NMN was thought for years to require dephosphorylation back to NR before entry. Then in 2019 Grozio et al. identified Slc12a8, a dedicated NMN transporter expressed prominently in the gut. The picture became more complicated.
The current synthesis: NMN appears to enter cells through a mix of pathways including direct transport and conversion-to-NR-then-back. NR enters through nucleoside transporters then gets phosphorylated to NMN inside. Both ultimately raise intracellular NAD+. The differences in efficiency between the two are smaller than either marketing camp claims.
> What this means in practice: The mechanistic argument doesn't decide the question. Either molecule will raise NAD+ in human tissue at appropriate doses. The relevant question is the human evidence base.
Both precursors have meaningful clinical evidence, but the trials have used different doses, populations, and outcomes, which makes direct comparison harder than it should be.
NR was studied first and longer. The most cited trials (Conze et al., 2019; Martens et al., 2018) showed reliable elevation of blood NAD+ at doses of 250–1000 mg per day in healthy older adults. Functional outcomes have been more mixed. Some trials show improvements in blood pressure, walking endurance, and inflammatory markers; others show NAD+ rises without clear functional change. The pattern is consistent with NR doing what it's supposed to do at the cellular level, with clinical translation depending on the population studied and the outcome measured.
NMN trials are more recent (most published from 2016 onward) and have generally shown both NAD+ elevation and functional benefit at doses of 250–600 mg per day. Mills et al. 2016 (the foundational mouse-to-human work), Yoshino et al. 2021 (insulin sensitivity in postmenopausal women with prediabetes), Pencina et al. 2023 (walking distance and blood NAD+), and Yamane et al. 2023 (muscle force, energy) form the core of the human dataset.
NMN has a slightly stronger functional outcomes record in recent trials, which may reflect either real biochemical advantage or the more rigorous design of newer studies (or both). NR has a longer safety track record because it's been around longer and is approved for sale in more jurisdictions. Neither molecule produces dramatic effects. Both are useful at the right dose for the right person.
This is where the two molecules diverge meaningfully. NR has full GRAS (Generally Recognised as Safe) status from the US FDA and is approved as a novel food ingredient in the EU. You can buy NR-based supplements in essentially any major market without restriction.
NMN's regulatory status is more complicated and varies by region. The EU has not yet approved NMN as a novel food, which means EU-based supplement brands operate in a gray zone. The US FDA in 2022 stated that NMN is excluded from the dietary supplement definition because it has been studied as a drug, though enforcement has been inconsistent. Some markets, including parts of Asia, treat NMN as freely available.
For consumers, this means:
AVEA does maintain a B2B-only NR Vitaliser product for partners and clinical contexts where NR is the appropriate fit, but our consumer-facing precursor focus is NMN.
NR has historically been more expensive at the molecule level due to a small number of patent-protected suppliers. NMN, with broader manufacturing and several patent expirations, has come down in price.
The formulation issue cuts both ways. Both molecules require quality manufacturing to be effective. The 2021 ConsumerLab analysis that showed many online NMN products contained essentially zero NMN was a wake-up call for the category. NR has had similar issues, though less publicly documented. The lesson is the same regardless of which molecule you pick: you need a verified source.
The AVEA NMN supplement uses Longevir, the only NMN currently manufactured in Europe, with enzymatic synthesis verified at greater than 99 percent purity. Available in 250 mg and 500 mg ("Forte") capsules. HPMC capsule, rice flour. Vegan, Halal certified. Each batch is independently tested in a Swiss lab before release.
The practical decision usually comes down to four factors:
For most adults trying to address an age-related NAD+ deficit and looking for the strongest current human data, NMN at 250–500 mg per day is the choice with the most evidence. The full mechanism context is at insights.avea-life.com/longevity/what-is-nmn-and-how-does-it-work/, and the broader benefits picture at insights.avea-life.com/longevity/nmn-benefits/.
If you've decided on NMN and want to dial in dose, "NMN dosage: 250 mg vs 500 mg vs higher amounts" walks through the dose-response evidence. If you want to step back and look at the full precursor landscape (NMN, NR, niacin, NAM), "NAD+ precursors compared: NMN, NR, niacin, NAM" extends this comparison. For mechanism, the LONGEVITY pillar "NAD+ Decline and How to Restore It" pulls everything together.
NAD+ is the molecule your cells use to make energy, repair DNA, and run almost every metabolic function that keeps you alive. By the time you're 50, your levels are roughly half what they were at 20, and that decline tracks closely with most of what we call "aging." This guide walks you through what NAD+ actually does, why it falls, what genuinely restores it, and how to tell if it's working. No miracles, no shortcuts, just the science.
Nicotinamide adenine dinucleotide, abbreviated NAD+, is a coenzyme present in every living cell on the planet. It shuttles electrons during metabolism, donates ribose groups to enzymes that repair damaged DNA, and acts as fuel for the sirtuin proteins that regulate cellular stress responses (Imai & Guarente, 2014).
Three of its jobs matter most for the way you feel day to day.
Your mitochondria use NAD+ to convert food into ATP, the molecule that powers everything from muscle contraction to thinking. When NAD+ runs low, mitochondrial output drops. You feel it as fatigue that doesn't lift after coffee or sleep, and as a longer recovery window after exertion.
Your cells accumulate roughly 100,000 DNA lesions per day from oxidation, UV exposure, and ordinary metabolism. The PARP enzymes that fix these lesions consume NAD+ as a substrate. Lower NAD+ means slower repair, which means more genomic damage accumulates over time. This is one of the recognised hallmarks of aging (López-OtÃn et al., 2023).
The seven sirtuin proteins regulate processes from inflammation to mitochondrial biogenesis to circadian rhythm. They all need NAD+ to function. Drop the NAD+ pool and the entire sirtuin network slows down with it.
NAD+ doesn't just gradually deplete with the years. Your body actively destroys more of it as you age, and three forces drive the decline.
By the time you're 50, intracellular NAD+ in muscle and liver tissue is typically 40 to 60 percent of what it was at 20. We cover the broader cellular context at The Hallmarks of Aging.
There's a lot of noise about NAD+ restoration. The honest landscape has four meaningful interventions, each with different evidence and trade-offs.
These are the molecules your salvage pathway uses to rebuild NAD+. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are the two most studied. Both raise blood and tissue NAD+ in humans (Mills et al., 2016; Pencina et al., 2023). NMN, in capsule form, is now the most commonly used precursor in serious longevity protocols. We cover the basics here: What is NMN and how does it work?.
Direct intravenous NAD+ raises blood levels quickly. The catch is that extracellular NAD+ doesn't enter cells efficiently in its native form. The molecule is largely broken down to nicotinamide before uptake, then reassembled inside the cell using the same salvage pathway you'd activate with an oral precursor. IV protocols also typically run between 300 and 800 euros per session. The full comparison is at NAD+ injections vs NAD+ supplements.
If CD38 is destroying your NAD+, slowing CD38 raises levels indirectly. Apigenin, the flavonoid found in parsley and chamomile, is a natural CD38 inhibitor with reasonable preclinical evidence (Escande et al., 2013). It's why apigenin appears alongside NMN in second-generation longevity formulations like the AVEA Booster.
Caloric restriction, time-restricted eating, vigorous exercise, and consistent sleep all upregulate NAMPT and the salvage pathway. None of these will double your NAD+ on their own, but without them no supplement strategy compounds the way it should.
NMN earned its position among NAD+ precursors for three reasons.
Here's where most marketing fails honest readers. Restoring NAD+ is not the same as reversing aging. It's bringing one important cofactor back closer to youthful levels, which removes a metabolic ceiling but doesn't undo decades of cellular wear.
What you can reasonably expect from a quality NMN protocol over 30 to 90 days:
> What you should not expect: rapid weight loss, dramatic skin transformation, the wholesale "feeling 20 again" promised by some marketing. Those claims exceed the evidence and they erode trust in the category.
You don't strictly need to test. But if you're investing real money and time, baseline data turns the protocol from faith into feedback.
The two relevant measures are circulating (plasma) NAD+ and intracellular NAD+. Intracellular is more meaningful because that's where NAD+ does its actual work, but it's harder to assay. Dried blood spot tests measure intracellular NAD+ in red blood cells and have become the practical standard for at-home longitudinal tracking.
The AVEA NAD+ Test Kit uses Jinfiniti's dried blood spot method. You take a baseline reading, start your protocol, then retest at 8 to 12 weeks. The number tells you whether your absorption, dosing, and pathway integrity are doing what they're supposed to. If NAD+ doesn't move, something is off, usually purity, dose, or methylation capacity. That feedback is more useful than another month of guessing.
If this guide was your first deep look at NAD+, the natural next reads in this cluster are "What is NAD+ and why it declines with age" for the underlying biochemistry, "NMN supplements: how they work, who they're for" for a narrower view of the precursor most people start with, and "NMN dosage: 250 mg vs 500 mg vs higher amounts" if you're already deciding what to take.
If you want to widen the lens beyond NAD+, the pillar articles on cellular energy and the 12 hallmarks of aging give you the broader context that NAD+ sits inside.
Most people who hear about NMN come at it from one of two angles. Either they're chasing a specific concern—fatigue, recovery, brain fog—and someone mentioned NMN as a possible lever, or they've read enough longevity content to know that NAD+ matters and they want to know what to do about it. This piece is for both. We'll walk through what NMN actually does inside your cells, who has the strongest evidence base for benefit, and how to know whether you're a likely responder.
NMN is nicotinamide mononucleotide. Chemically, it's one half of NAD+, specifically the half that contains the nicotinamide ring connected to a sugar (ribose) and a phosphate group. When NMN gets inside a cell, an enzyme called NMNAT joins it to the second half (an adenine-containing nucleotide) to produce a fresh NAD+ molecule.
Why not just take NAD+ directly? Two reasons:
Taking NMN works around both problems. It's stable enough to survive digestion (with a quality formulation), and once it's in the bloodstream, dedicated transporters move it into cells where the salvage pathway converts it to NAD+ in a single step.
Your cells have a recycling loop called the salvage pathway that constantly breaks NAD+ down (during normal use by sirtuins, PARPs, and CD38) and rebuilds it from nicotinamide. The bottleneck enzyme in this loop is NAMPT, which converts nicotinamide back into NMN. With age, NAMPT activity falls. The recycling loop can't keep up with consumption, and NAD+ levels drop.
NMN bypasses the NAMPT step. By giving your cells the molecule that NAMPT would have produced, you're delivering raw material one step downstream of the bottleneck. The downstream enzyme NMNAT then converts NMN to NAD+ without limitation.
> This is the mechanistic reason NMN consistently raises NAD+ in human studies even when other interventions (exercise, fasting) only push the bottlenecked NAMPT enzyme harder. The full picture of how this fits into the cellular landscape is at insights.avea-life.com/longevity/what-is-nmn-and-how-does-it-work/.
Across roughly a dozen randomised controlled trials in humans, NMN has shown the strongest results in three populations.
This is the broadest and best-supported group. NMN at 250–500 mg per day raises blood and intracellular NAD+ in healthy middle-aged and older adults across multiple trials (Mills et al., 2016; Yoshino et al., 2021; Pencina et al., 2023). The functional outcomes that follow include improved walking distance, modest gains in muscle force, and self-reported energy and sleep improvements. AVEA's customer survey of 280 NMN users found 80 percent reported noticeable energy and focus improvement within 30 days, and 73 percent reported better sleep at three months.
A trial of NMN in postmenopausal women with prediabetes showed measurable improvements in insulin sensitivity and skeletal muscle insulin signalling at 250 mg per day for 10 weeks (Yoshino et al., 2021). This doesn't make NMN a glucose drug, but it suggests the metabolic ceiling NAD+ supports is meaningful in this population.
Walking endurance, grip strength, and biological-age proxies have all improved modestly in NMN trials in adults over 60 (Pencina et al., 2023; Yamane et al., 2023). The size of the gains is moderate. NMN is not a substitute for resistance training or cardiovascular exercise, but it appears to remove a metabolic limit that lets training translate into greater functional gain.
This is where most NMN content goes wrong. Honest answers about non-responders matter as much as the upside.
Across the population that does respond, the timeline is reasonably consistent.
Subtle. You may notice a slightly easier wake-up or fewer afternoon energy dips. Many people report nothing yet. NAD+ is rising in tissue but functional consequences haven't compounded.
This is when most responders notice something. Energy and focus are the most commonly reported changes. In AVEA's customer data, 80 percent of NMN users described a noticeable improvement at this point. Sleep quality improvements lag slightly behind, often appearing in the second month.
The deeper changes show up. Recovery time after exercise shortens. Skin can look fractionally better thanks to improved microcirculation and DNA repair capacity. Sleep improvements become more consistent. In AVEA's internal case study, a 43-year-old taking 500 mg NMN daily roughly doubled intracellular NAD+ in three weeks, measured by Jinfiniti dried blood spot testing. The functional changes followed across the next two months.
> If you're not noticing anything by week 8 or 10 on a quality NMN, two questions to ask. First, is the product actually NMN? A 2021 ConsumerLab survey found that more than half of NMN sold online contained essentially zero NMN. Second, are the surrounding factors (sleep, exercise, alcohol intake) actively working against you? NMN compounds with good inputs and stalls without them.
The supplement industry has a transparency problem, and NMN sits near the centre of it. Two issues matter most.
Sourcing isn't the most exciting part of supplement choice, but it's the part that determines whether the molecule on the label is the molecule in your body. We cover the broader benefits picture at insights.avea-life.com/longevity/nmn-benefits/, and there's a longer-form review of the AVEA NMN protocol at insights.avea-life.com/longevity/avea-supplement-review-does-avea-nmn-booster-actually-really-work/.
If you're trying to decide between dose levels, "NMN dosage: 250 mg vs 500 mg vs higher amounts" walks through the dose-response curve. If you want a head-to-head with the other major precursor, "NMN vs NR (nicotinamide riboside): the complete comparison" covers both molecules side by side. For the full mechanism behind everything we've discussed here, the LONGEVITY pillar "NAD+ Decline and How to Restore It" is the broader frame.
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!